Skip to main content
Fig. 6 | Cancer Nanotechnology

Fig. 6

From: Anti-EGFR conjugated nanoparticles to deliver Alpelisib as targeted therapy for head and neck cancer

Fig. 6

a Schematic illustration of the experiments in c and d: 24 h after seeding, cells were treated with 0.5 µM free Alpelisib or with the same amount of drug loaded in nanoparticles. The drug was left for 24 h, and cell viability (XTT assay) and proteins (Western blot) were analyzed. In some plates, culture medium was replaced by drug-free medium after 6 h of incubation with the different compounds, and cell viability and proteins were analyzed 18 h later. b Cell viability was measured after treatment of Cal33 cells with increasing concentrations of free Alpelisib for 24 h to determine inhibitory concentrations (IC) 25, 50 and 75. R squared: goodness of fit to a Log(inhibitor) vs. normalized response variable slope regression curve. Mean ± SEM. The red dot indicates the concentration used for experiments in c and d (IC25 = 0.5 µM). c Cell viability analysis of Cal33 cells treated with 0.5 µM free Alpelisib or in nanoparticles for 24 h or for 6 h followed by 18 h incubation with drug-free media. The dotted line indicates 100% cell survival of untreated cells. Control cells were treated with the vehicle of Alpelisib (DMSO). Equivalent concentrations of empty NP or ACNP to nanoparticles loaded with Alpelisib were used. Mean ± SEM. Ordinary one-way ANOVA, Tukey´s multiple comparisons test, In blue pVal < 0.0001, in green pVal < 0.05. d Western blot (WB) analysis of the indicated proteins/phosphoproteins

Back to article page